Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBlue Cross Blue Shield ND Prior Auth Policy Update…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North DakotaPolicy N/A

    Medicaid Expansion Restricted Use Drug Precertification List

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Dakota policy alerts

    Know when Blue Cross Blue Shield - North Dakota releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines drugs subject to precertification (prior approval) and limited dispensing for BCBSND Medicaid Expansion members, and indicates processing through medical or pharmacy benefits as appropriate.

    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyMedicaid Expansion Restricted Use Drug Precertification List
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrecertification (Prior Approval) is required for restricted use drugs; both brand and generic equivalents require precertification.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    50+restricted-use drugs listed
    95250, A4238…example codes included
    CGM codesCGM device/supply codes named
    Multipleinjection/biologic codes

    Coverage Criteria and Processing Rules

    Coverage criteria and processing

    Covered when ALL of the following processing and coverage conditions are met:

    Precertification (Prior Approval) is required for drugs listed on the Restricted Use Drug list; both brand name drugs and their generic equivalents require prior approval.
    For medications not on the Restricted Use Drug list, FDA or compendia‑supported indications are required.
    Prior authorization and benefit determination (medical vs. pharmacy) should follow the Preferred Drug List (PDL) and the Medical Policy: Medications and Diabetic Supplies Payable on the Pharmacy Benefit as applicable.
    Medications administered by an individual that do not require professional administration are considered self‑administered and are typically not covered under the medical benefit; these items are processed through pharmacy point‑of‑sale when included on the Department of Human Services Preferred Drug List or Preferred Diabetic Supplies List.
    Specific HCPCS/CPT/J‑codes enumerated in the policy are subject to the processing rules described above and must be billed according to the identified benefit (medical vs pharmacy) and any applicable prior authorization requirements.

    Coverage and billing routing

    Coverage stance for self‑administered medications and routing of listed codes:

    Self‑administered medications are typically not covered under the medical benefit and should be billed through the pharmacy benefit when they appear on the Department of Human Services Preferred Drug List or Preferred Diabetic Supplies List.
    Examples: Continuous glucose monitoring (CGM) and supply codes (e.g., 95250, A4238, A4239, A9276, A9277, A9278, E2102, E2103) included in this policy are processed via pharmacy point‑of‑sale per the Department of Human Services Preferred Diabetic Supplies List.
    A broad set of injectable, biologic, clotting factor, biosimilar, and device codes listed in the policy (for example J0139 and other J‑series codes) are enumerated for routing and prior authorization purposes and are subject to the processing rules under the pharmacy or medical benefit as indicated in the policy.

    Representative Codes and Code Lists

    Representative J-codes from listHCPCSCovered
    J3262Tocilizumab (ACTEMRA IV)
    J9042Brentuximab (ADCETRIS)
    J1552Immune globulin (ALYGLO)
    CGM and supply codesCPT | HCPCSCovered
    95250Ambulatory continuous glucose monitoring; equipment and services
    A4238Supply allowance for adjunctive CGM, 1 month supply = 1 unit
    CGM and related suppliesCPT | HCPCS | mixedCovered
    95250Ambulatory continuous glucose monitoring via subcutaneous sensor for a minimum of 72 hours; office services including sensor placement, calibration, training, and printout
    A4238Supply allowance for adjunctive continuous glucose monitor (CGM), 1 month supply = 1 unit
    A4239Supply allowance for non-adjunctive, non-implanted CGM, 1 month supply = 1 unit
    A9276Sensor; invasive (subcutaneous), disposable, one unit = 1 day supply
    A9277Transmitter; external, for use with interstitial CGM system
    A9278Receiver (monitor); external, for use with interstitial CGM system
    E2102Adjunctive continuous glucose monitor or receiver
    E2103Non-adjunctive, non-implanted continuous glucose monitor or receiver
    Selected injectables, biologics, factor products, biosimilars, and device codesHCPCS | CPT | mixedCovered
    J0139Injection, adalimumab, 20 mg
    J1748Injection, infliximab-dyyb, 10 mg
    J7170Injection, emicizumab-kxwh, 0.5 mg
    J7200Injection, factor IX (recombinant), Rixubis, per IU
    J7205Injection, factor VIII Fc fusion protein (Eloctate), per IU
    J7527Everolimus, oral, 0.25 mg
    Q5137Injection, ustekinumab-auub (Wezlana), biosimilar, subcutaneous, 1 mg
    S1034Artificial pancreas device system including CGM and insulin pump
    Drug indications requirement
    RequirementFor medications not on the Restricted Use List, FDA or compendia‑supported indications are required.
    ScopeApplies when a drug is not enumerated on the BCBSND Medicaid Expansion Restricted Use List; clinical indication must match FDA labeling or accepted compendia.
    Reference guidanceSee Drug Indications (Medicaid Expansion) on BCBSND for details and acceptable compendia support.

    Provider Actions and Billing Guidance

    Prior Authorization

    Precertification required for restricted use drugs

    Precertification (Prior Approval) is required for restricted use drugs; both brand name drugs and generic equivalents require precertification before coverage or dispensing.

    Billing Rule

    Pharmacy POS processing and self‑administered medication billing

    Medications that are self‑administered (administered by an individual and not requiring professional administration) are typically not covered under the medical benefit and listed codes are processed through pharmacy point‑of‑sale according to the Department of Human Services Preferred Drug List or Preferred Diabetic Supplies List.

    • Examples of codes processed via pharmacy POS include 95250 (ambulatory continuous glucose monitoring) and A4238 (CGM supply allowance).

    Definitions

    Restricted Use Drug
    DefinitionA prescription medication that may require precertification (Prior Approval) and/or be subject to a limited dispensing amount.
    PrecertificationBoth brand name drugs and generic equivalents require prior authorization when listed as restricted use.
    Dispensing limitsDrugs on the Restricted Use List may be subject to limited dispensing amounts as specified by policy.
    Medical Drug
    DefinitionA drug covered under the medical benefit that requires precertification (Prior Approval).
    ActionPrior authorizations information for medical drugs can be found on the BCBSND Policies & Prior Authorization page.
    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyMedicaid Expansion Restricted Use Drug Precertification List
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrecertification (Prior Approval) is required for restricted use drugs; both brand and generic equivalents require precertification.
    SourceLink
    On This Page
    Coverage Criteria and Processing RulesRepresentative Codes and Code ListsProvider Actions and Billing GuidanceDefinitions
  1. See Medical Policy: Medications and Diabetic Supplies Payable on the Pharmacy Benefit for billing routing and benefit determination.
  2. RoutingMedical drugs requiring prior approval are processed under the medical benefit unless otherwise indicated.
    Preferred Drug List (PDL)
    DefinitionPreferred Drug List (PDL): list of medications that are preferred and processed by pharmacy point‑of‑sale systems.
    UseConsult the most recent PDL to determine additional precertification/prior approval requirements and benefit (pharmacy vs medical).
    Processing noteCertain codes (e.g., CGM and supplies) are processed through pharmacy point‑of‑sale per Department of Human Services PDL or Preferred Diabetic Supplies List.
    Self-administered medications
    DefinitionMedications administered by an individual that do not require professional administration by a healthcare provider and are generally not covered under the medical benefit.
    Coverage routingSelf‑administered medications are typically billed through the pharmacy benefit rather than the medical benefit.
    Policy pointerSee Medical Policy: Medications and Diabetic Supplies Payable on the Pharmacy Benefit for details.
    Pharmacy point of sale processing
    DefinitionProcessing of certain drug and supply codes through pharmacy systems in accordance with the Department of Human Services Preferred Drug List or Preferred Diabetic Supplies List.
    ExamplesCGM and supply codes included in this policy (e.g., 95250, A4238, A4239, A9276–A9278, E2102–E2103) are processed via pharmacy point‑of‑sale.
    InstructionConsult DHS Preferred Drug or Preferred Diabetic Supplies Lists to determine point‑of‑sale processing and benefit determination.